Se and Retroperitoneal lymphadenopathy - a phase IV clinical study of FDA data

Summary:

Retroperitoneal lymphadenopathy is reported as a side effect among people who take Se (selenium), especially for people who are male, 60+ old, also take Zometa, and have Bone density decreased.

The phase IV clinical study analyzes which people have Retroperitoneal lymphadenopathy when taking Se. It is created by eHealthMe based on reports of 5,331 people who have side effects when taking Se from the FDA, and is updated regularly.

What is Se?

Se has active ingredients of selenium. eHealthMe is studying from 5,604 Se users. Check the latest studies of Se.

What is Retroperitoneal lymphadenopathy?

Retroperitoneal lymphadenopathy (disease of lymph node between peritoneum and the posterior abdominal wall) is found to be associated with 186 drugs and 212 conditions by eHealthMe. Check the latest studies of Retroperitoneal lymphadenopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

5,331 people reported to have side effects when taking Se.
Among them, 24 people (0.45%) have Retroperitoneal lymphadenopathy.

Could Se cause Retroperitoneal lymphadenopathy?

Among these 24 people:

What is the gender of people who have Retroperitoneal lymphadenopathy when taking Se? *

female: 0.0 %
male: 100 %

What is the age of people who have Retroperitoneal lymphadenopathy when taking Se? *

What are other drugs people take besides Se? *

What are other side effects people have besides Retroperitoneal lymphadenopathy? *

Anaemia (lack of blood): 24 people, 100.00%
Tooth Abscess (pus formation in tooth): 24 people, 100.00%
Bone Disorder: 24 people, 100.00%
Injury: 24 people, 100.00%
Oedema Peripheral (superficial swelling): 22 people, 91.67%
Fainting (loss of consciousness and postural tone): 21 people, 87.50%
Osteonecrosis Of Jaw (death of bone of jaw): 21 people, 87.50%
Sinus Bradycardia (an unusually slow heartbeat due to heart disease): 19 people, 79.17%
Blood Urea Increased: 18 people, 75.00%
Lymphocyte Count Decreased: 17 people, 70.83%

What are the existing conditions these people have? *

Prostate Cancer: 10 people, 41.67%
Bone Density Decreased: 10 people, 41.67%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 9 people, 37.50%
Bone Loss: 4 people, 16.67%
Metastases To Bone (cancer spreads to bone): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Se and have Retroperitoneal lymphadenopathy?

- Check whether Retroperitoneal lymphadenopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Se:

Se (5,604 reports)

Browse all side effects of Se:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Retroperitoneal lymphadenopathy:

Retroperitoneal lymphadenopathy (186 drugs)

Browse all the conditions that are associated with Retroperitoneal lymphadenopathy:

Retroperitoneal lymphadenopathy (212 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on selenium (the active ingredients of Se) and Se (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.